BiotechTube
CellforCure

CellforCure

Les Ulis, France· Est.
cellandgene.seqens.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $65M

Overview

CELLforCURE is a leading European CDMO for cell and gene therapies, offering comprehensive development and manufacturing services from a single 10,000 m² site. With a 15-year track record, it has deep expertise in technology transfer and commercial-scale production, evidenced by over 600 autologous CAR-T doses and 10,000 allogeneic clinical vials manufactured. Acquired by the SEQENS Group in 2023, the company leverages its history as both a CDMO and a captive manufacturer for Novartis to provide clients with a unique 'one-stop-shop' solution for accelerating therapies to market.

OncologyOther (Cell & Gene Therapy)

Technology Platform

Integrated CDMO platform with 7 independent, modular GMP manufacturing lines for autologous and allogeneic cell therapies. Includes 48 cleanrooms, an 800 m² QC lab, and a 300 m² process development lab for end-to-end services from tech transfer to commercial production.

Funding History

2
Total raised:$65M
Series B$40M
Series A$25M

Opportunities

The rapid growth of the cell and gene therapy market, coupled with a widespread industry reliance on outsourcing for GMP manufacturing, presents a massive demand for specialized CDMO services.
CELLforCURE's large-scale, commercial-ready capacity and proven track record in producing both autologous and allogeneic therapies position it uniquely to capture lucrative late-stage and commercial contracts from biotech and pharma companies.

Risk Factors

The company faces significant risks including client concentration, where the loss of a major program could severely impact revenue; intense competition from other global CDMOs; and stringent regulatory compliance requirements where any failure could result in operational shutdowns and reputational damage.
Its success is also tied to the funding health and clinical success of its biotech clients.

Competitive Landscape

CELLforCURE competes in a crowded global CDMO market for cell and gene therapies, facing large players like Lonza, Catalent, and Charles River Laboratories, as well as specialized pure-play ATMP CDMOs. Its key differentiators are its very large, dedicated European facility with commercial-scale proof points, its unique history as a captive manufacturer for Novartis, and its integrated 'one-stop-shop' model under the SEQENS umbrella.

More companies in Cell & Gene Therapy →More companies in France →